| Trevi Therapeutics Inc (TRVI) | |||
|---|---|---|---|
| 3.01 0.07 (2.38%) | 05-07 12:20 | ||
| Open: | 2.94 | Pre. Close: | 2.94 |
| High: | 3.01 | Low: | 2.94 |
| Volume: | 10,930 | Market Cap: | 208(M) |
| Stock Technical Analysis | |
|---|---|
| Overall: |  |
| Target: | Six months: 3.80  One year: 4.43 |
| Support: | Support1: 2.69 Support2: 2.35 |
| Resistance: | Resistance1: 3.25 Resistance2: 3.80 |
| Pivot: | 2.84  |
| Moving Averages: | MA(5): 2.97 MA(20): 2.83 MA(100): 2.31 MA(250): 2.17 |
| MACD: | MACD(12,26): Signal(12,26,9): -0.03 |
| %K %D: | %K(14,3): 79.58 %D(3): 78.75 |
| RSI: | RSI(14): 53.29 |
| 52-Week: | High: 4 Low: 0.97 Change(%): -0.7 |
| Average Vol(K): | 3-Month: 305 10-Days: 107 |
| Prices Prediction (Update @5:00pm) | ||
|---|---|---|
| If tomorrow: | Open lower | Open higher |
| High: | 3.073 - 3.091 | 3.091 - 3.107 |
| Low: | 2.881 - 2.899 | 2.899 - 2.916 |
| Close: | 2.913 - 2.943 | 2.943 - 2.97 |
| Price, MAs and Bollinger Bands |
|---|
| Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ TRVI ] has closed below upper band by 23.3%. Bollinger Bands are 14.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
| Company profile |
|---|
| Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut. |
| Stock chart |
|---|
 |
| Financial Analysis | |
|---|---|
| Price to Book Value: | Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
| Price to Earnings: | Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
| Discounted cash flow: | Neutral |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
| Return on Assets: | Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
| Return on Equity: | Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
| Debt to Equity: | Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. | |
| Stock Basics & Statistics | |
|---|---|
| Exchange: NASDAQ Global Market | |
| Sector: Healthcare | |
| Industry: Biotechnology | |
| Shares Out. (M) | 70.44 |
| Shares Float (M) | 39.85 |
| % Held by Insiders | 1.28 |
| % Held by Institutions | 89.95 |
| Shares Short (K) | 898 |
| Shares Short Prior Month (K) | 1070 |
| Stock Financials | |
|---|---|
| EPS | -0.290 |
| Book Value (p.s.) | 1.210 |
| Profit Margin | |
| Operating Margin | |
| Return on Assets (ttm) | -20.0 |
| Return on Equity (ttm) | -30.6 |
| Qtrly Rev. Growth | |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | -0.480 |
| Qtrly Earnings Growth | |
| Operating Cash Flow (M) | -31.71 |
| Levered Free Cash Flow (M) | -21.97 |
| Stock Valuation | |
|---|---|
| PE Ratio | -10.34 |
| PEG Ratio | |
| Price to Book value | 2.48 |
| Price to Sales | |
| Price to Cash Flow | -6.66 |
| Stock Dividends | |
|---|---|
| Dividend | |
| Dividend Yield | |
| Dividend Growth | |
